In our study, BEA and BEA G1 concurrently inhibited the activation of ERK1/2, JNK, p38 MAPK, NF-κB p65, STAT3, and MITF in A375SM melanoma cells, suggesting that the natural compounds may effectively inhibit aggressive melanoma by targeting multiple oncogenic molecular pathways. The gene discussed is MAPK3; the disease is melanoma.